For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
5
views
17
references
 Top references
cited by
3
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      353
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Validity and Reliability of COPD-6 Device for Detecting Chronic Obstructive Pulmonary Disease in High-Risk Individuals

      research-article

      Read this article at

      ScienceOpenPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background:

          The current study was done to evaluate the validity and reliability of the Vitalograph COPD-6 portable device for detecting chronic obstructive pulmonary disease (COPD) in high-risk individuals in Iran.

          Materials and Methods:

          This research was a cross-sectional descriptive study. Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and FEV1/FVC using standard spirometer and FEV1, FEV6, and FEV1/FEV6 with COPD- 6 device were measured and recorded. Descriptive analysis was done.

          Results:

          19 of 122 patients (15.6%) were diagnosed with COPD. The COPD-6 had an acceptable performance for detecting COPD as assessed by the area under the receiver operating characteristic (ROC) curve (0.72 ; 95% CI: 0.42–0.86), with an average sensitivity of 84% and specificity of 98%, positive predictive value of 89%, and negative predictive value of 97%. The positive likelihood ratio resulted was 42 and the negative likelihood ratio was 0.16.

          Conclusion:

          COPD-6 is a validate and reliable device for detecting COPD in non-specialized health care settings and the best cut-off point for FEV1/FEV6 ratio is 0.72.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary

          Claus F. Vogelmeier, Gerard J. Criner, Fernando J Martínez … (2017)
          American Journal of Respiratory and Critical Care Medicine, 195(5), 557-582
          Article 0 comments Cited 702 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure

            Bram Rochwerg, Laurent Brochard, Mark W Elliott … (2017)
            Noninvasive mechanical ventilation (NIV) is widely used in the acute care setting for acute respiratory failure (ARF) across a variety of aetiologies. This document provides European Respiratory Society/American Thoracic Society recommendations for the clinical application of NIV based on the most current literature. The guideline committee was composed of clinicians, methodologists and experts in the field of NIV. The committee developed recommendations based on the GRADE (Grading, Recommendation, Assessment, Development and Evaluation) methodology for each actionable question. The GRADE Evidence to Decision framework in the guideline development tool was used to generate recommendations. A number of topics were addressed using technical summaries without recommendations and these are discussed in the supplementary material. This guideline committee developed recommendations for 11 actionable questions in a PICO (population–intervention–comparison–outcome) format, all addressing the use of NIV for various aetiologies of ARF. The specific conditions where recommendations were made include exacerbation of chronic obstructive pulmonary disease, cardiogenic pulmonary oedema, de novo hypoxaemic respiratory failure, immunocompromised patients, chest trauma, palliation, post-operative care, weaning and post-extubation. This document summarises the current state of knowledge regarding the role of NIV in ARF. Evidence-based recommendations provide guidance to relevant stakeholders.
            Article 0 comments Cited 313 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.

              Bartolome R Celli, Marc Decramer, Jadwiga Wedzicha … (2015)
              Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and resource use worldwide. The goal of this Official American Thoracic Society (ATS)/European Respiratory Society (ERS) Research Statement is to describe evidence related to diagnosis, assessment, and management; identify gaps in knowledge; and make recommendations for future research. It is not intended to provide clinical practice recommendations on COPD diagnosis and management. Clinicians, researchers, and patient advocates with expertise in COPD were invited to participate. A literature search of Medline was performed, and studies deemed relevant were selected. The search was not a systematic review of the evidence. Existing evidence was appraised and summarized, and then salient knowledge gaps were identified. Recommendations for research that addresses important gaps in the evidence in all areas of COPD were formulated via discussion and consensus. Great strides have been made in the diagnosis, assessment, and management of COPD as well as understanding its pathogenesis. Despite this, many important questions remain unanswered. This ATS/ERS Research Statement highlights the types of research that leading clinicians, researchers, and patient advocates believe will have the greatest impact on patient-centered outcomes.
              Article 0 comments Cited 74 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Tanaffos
                Journal ID (iso-abbrev): Tanaffos
                Journal ID (publisher-id): Tanaffos
                Journal ID (pmc): Tanaffos
                Title: Tanaffos
                Publisher: National Research Institute of Tuberculosis and Lung Disease
                ISSN (Print): 1735-0344
                ISSN (Electronic): 2345-3729
                Publication date (Print): July 2020
                Volume: 19
                Issue: 3
                Pages: 201-207
                Affiliations
                [1 ] Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran,
                [2 ] Resident of Internal medicine, Isfahan University of Medical Science, Isfahan, Iran,
                [3 ] Department of Community Medicine, Isfahan University of Medical Science, Isfahan, Iran
                Author notes
                Correspondence to: Sami R Address: Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Email address: r.sami@ 123456med.mui.ac.ir
                Article
                Publisher ID: Tanaffos-19-201
                PMC ID: 8008408
                SO-VID: a548f758-fad2-4019-9ae9-d8bc02dd472f
                Copyright © Copyright© 2020 National Research Institute of Tuberculosis and Lung Disease
                License:

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

                History
                Date received : 21 October 2019
                Date accepted : 06 May 2020
                Categories
                Subject: Original Article

                Keywords: chronic obstructive pulmonary disease,copd,copd-6,fev1/fev6 ratio,portal spirometer
                Data availability:
                Keywords: chronic obstructive pulmonary disease, copd, copd-6, fev1/fev6 ratio, portal spirometer

                Comments

                Comment on this article

                Similar content353

                See all similar

                Cited by3

                See all cited by

                Most referenced authors311

                See all reference authors